Vandetanib

CHEMBL24828 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
475.4 g/mol
LogP
4.9
Phase
4

This targeted therapy blocks multiple receptors (VEGFR, EGFR, and RET) involved in tumor growth and blood vessel formation, and is used to treat symptomatic or progressive medullary thyroid cancer that cannot be surgically removed. It is taken as a daily oral tablet. It can cause a serious prolongation of the heart's electrical rhythm (QT prolongation), requiring regular heart monitoring.

Khối lượng phân tử

475,4000 g/mol

LogP

4,90

TPSA

59,50 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1

InChI

InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)

Molecular Formula

C22H24BrFN4O2

HBD / HBA

1 / 7

Liên kết có thể quay

6

Nguyên tử nặng

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This targeted therapy blocks multiple receptors (VEGFR, EGFR, and RET) involved in tumor growth and blood vessel formation, and is used to treat symptomatic or progressive medullary thyroid cancer that cannot be surgically removed. It is taken as a daily oral tablet. It can cause a serious prolongation of the heart's electrical rhythm (QT prolongation), requiring regular heart monitoring.

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Yes, Vandetanib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL24828. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3081361. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.